

- Imaging cardiac repair and regeneration:** Thackeray and Bengel look at the evolution of regenerative heart medicine and call for imaging adaptation to provide tools to evaluate molecular mechanisms underlying endogenous healing. . . . *Page 549*
- PET/CT in local ablative therapies:** Aarntzen and colleagues systematically review current literature on the use of ^{18}F -FDG PET/CT to monitor the efficacy of local ablative therapies, identify patterns across studies, and offer recommendations for the future. . . . *Page 551*
- PET/CT for prostate RT planning:** Calais and colleagues provide an educational overview of the literature on the effect of PET/CT on prostate radiotherapy planning, the potential of various PET/CT strategies and tracers on planning, and current relevant investigations. . . . *Page 557*
- ^{18}F radiochemistry:** Bernard-Gauthier and colleagues focus on recent ^{18}F -labeling methodologies for B- ^{18}F , Si- ^{18}F , Al- ^{18}F , and iodine (III)-mediated radiofluorination via spirocyclic iodonium ylide technology. . . . *Page 568*
- Challenges in nuclear endocrinology:** Täieb and colleagues offer perspective on the future of nuclear endocrinology in prognostication and tumor grading, therapeutic drug monitoring, and immunology applications. . . . *Page 573*
- PET/CT and HNSCC:** Rohde and colleagues determine whether staging of head and neck squamous cell carcinoma by upfront ^{18}F -FDG PET/CT predicts survival better than traditional imaging strategies based on chest x-ray or CT plus MR imaging. . . . *Page 575*
- ^{166}Ho radioembolization:** Prince and colleagues investigate the efficacy of and response to ^{166}Ho microsphere radioembolization in patients with liver metastases refractory to systemic therapy and ineligible for surgical resection. . . . *Page 582*
- Interim PET and PTCL:** Cottreau and colleagues ask whether therapeutic response in peripheral T-cell lymphoma as assessed with PET/CT plus baseline total metabolic tumor volume can identify early relapse or refractory disease. . . . *Page 589*
- BSI in ^{223}Ra therapy:** Fosbøl and colleagues detail the prognostic value of the scintigraphy-derived bone scan index in patients with advanced metastatic castration-resistant prostate cancer under treatment with $^{223}\text{RaCl}_2$ *Page 596*
- Tumor volume in ^{18}F -FET PET and 3D MRSI:** Mauler and colleagues compare the results of ^{18}F -FET PET imaging of amino acid transport and proton MR spectroscopy imaging of cell turnover ratios in defining tumor extent of cerebral gliomas. . . . *Page 603*
- Targeting pontine glioma:** Oyen and Jones report on the value of molecular imaging of target expression as a tool for in vivo immunohistochemistry and preview a related study in this issue of *JNM*. . . . *Page 610*
- Drug-uptake and tumor morphology in DIPG:** Veldhuijzen van Zanten and colleagues combine data from a ^{89}Zr -bevacizumab study and autopsy to analyze multiregional in vivo and ex vivo uptake, tumor histology, and vascular morphology in end-stage diffuse intrinsic pontine glioma. . . . *Page 612*
- ^{177}Lu SPECT/CT kidney imaging:** Tran-Gia and Lassmann describe an optimal setup for activity determination of ^{177}Lu -based SPECT/CT renal imaging using 3D-printed phantoms and 2 commercially available methods. . . . *Page 616*
- ^{68}Ga -THP-PSMA PET/CT in prostate cancer:** Hofman and colleagues monitor the safety and efficacy of a ^{68}Ga -prostate-specific membrane antigen agent that features single-step kit-based radiolabeling for PET/CT imaging in prostate cancer before prostatectomy. . . . *Page 625*
- PSMA-1007 in prostate cancer recurrence:** Giesel and colleagues assess the potential of ^{18}F -prostate-specific membrane antigen-1007 PET for disease localization in patients with biochemical recurrence of prostate cancer after local treatment. . . . *Page 632*
- Dose calibrators and ^{68}Ga :** Bailey and colleagues report on a systematic miscalibration during site validation of a multicenter clinical PET trial using ^{68}Ga , manifested as a consistent underestimation in quantitative accuracy in a range of PET systems. . . . *Page 636*
- Dual-labeled PSMA-11:** Baranski and colleagues describe development of dual-labeled prostate-specific membrane antigen inhibitors derived from ^{68}Ga -PSMA-11 to allow accurate intraoperative detection of prostate-specific membrane antigen-positive tumors. . . . *Page 639*
- Cold-antibody boost after α -particle therapy:** Palm and colleagues report on simulations of penetration of radiolabeled monoclonal antibodies into microtumors with radii of up to 400 μm and calculate optimization of an added boost for different tumor sizes. . . . *Page 646*
- ^{123}I -mIBG planar and SPECT HMRS:** Alvi and colleagues report on a semiautomated methodology for assessing heart-to-mediastinum ratio with a dedicated cardiac multipinhole SPECT/CT system and correlate SPECT-derived lower normal limits with those from planar derived ratios. . . . *Page 652*
- ^{11}C -MeNER PET and noradrenaline in PD:** Nahimi and colleagues use PET and a highly selective radiolabeled inhibitor of noradrenaline transporters to map transporter density in groups of patients with Parkinson disease and controls. . . . *Page 659*
- Pretreatment 5-HTT binding and remission:** Ananth and colleagues investigate whether 5-HTT and 5-HT $_{1A}$ binding as assessed on PET imaging can improve prediction of posttreatment remission status in patients with major depressive disorder. . . . *Page 665*
- ^{18}F -THK5351 PET and pathology correlation:** Harada and colleagues examine spatial patterns of tracer binding, amyloid- β , tau, and gliosis in an individual with autopsy-confirmed Alzheimer disease who underwent ^{18}F -THK5351 and ^{11}C -Pittsburgh compound B PET before death. . . . *Page 671*
- PET imaging of tau aggregates:** Honer and colleagues detail preclinical in vitro and in vivo characterization of 3 novel ^3H -labeled compounds that bind specifically to tau aggregates and have potential as future PET tracers. . . . *Page 675*
- Lower mGlu5 in alcohol dependence:** Leurquin-Sterk and colleagues use dynamic ^{18}F -FPET imaging to investigate cerebral metabotropic glutamate receptor subtype 5 availability in alcohol-dependent individuals and controls. . . . *Page 682*
- Intragastric meal distribution:** Orthey and colleagues evaluate visual assessments of fundic accommodation from solid-meal gastric-emptying scintigraphy and describe software developed to quantify the results of such scintigraphy. . . . *Page 691*
- PET and NMDA GluN2B receptors:** Krämer and colleagues describe development of ^{11}C -Me-NB1 as a PET tracer for imaging GluN1- and GluN2B-containing *N*-methyl-D-aspartate receptors and investigate eliprodil dose-dependent receptor occupancy in rats. . . . *Page 698*
- ^{177}Lu -Lilotomab satetraxetan dosimetry:** Blakkisrud and colleagues document biodistribution of a novel antibody-radiionuclide conjugate as well as absorbed doses to organs at risk in patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. . . . *Page 704*